A Phase I Study of CS1002 in Subjects With Advanced Solid Tumors
Status:
Completed
Trial end date:
2020-09-21
Target enrollment:
Participant gender:
Summary
This is an open label, dose escalation phase I study to evaluate the clinical safety,
tolerability in subjects with advanced solid tumors, and to establish the Maximum Tolerated
Dose (MTD#, if any). This study is composed of two dose level: 1 and 3 mg/kg.